Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery

• Published in: Journal of ocular pharmacology and therapeutics Vol. 29; no. 6; p. 566
• Main Authors: Paula, Jayter Silva, Ribeiro, Vanessa Raquel Coimbra, Chahud, Fernando, Cannellini, Roberta, Monteiro, Tassia Cristina, Gomes, Elionai Cassiana de Lima, Reinach, Peter Sol, Rodrigues, Maria de Lourdes Veronese, Silva-Cunha, Armando
• Format: Journal Article
• Language: English
• Published: United States 01.07.2013
• Subjects: Animals; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Bevacizumab; Chromatography, Gel; Cicatrix - etiology; Cicatrix - metabolism; Cicatrix - pathology; Cicatrix - prevention & control; Conjunctiva - surgery; Drug Carriers - chemistry; Drug Implants; Female; Fibroblasts - drug effects; Fibroblasts - metabolism; Fibroblasts - pathology; Filtering Surgery - adverse effects; Glaucoma - surgery; Polyurethanes - chemistry; Rabbits; Surface Properties; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 1557-7732
• DOI: 10.1089/jop.2012.0136

Vascular endothelial growth factor (VEGF) may contribute to the scarring process resulting from glaucoma filtration surgery, since this cytokine may stimulate fibroblast proliferation. The aim of this study was to describe a new bevacizumab-loaded polyurethane implant (BPUI) and to evaluate its effectiveness as a new drug delivery system of anti-VEGF antibody in a rabbit model of glaucoma filtration surgery. An aqueous dispersion of polyurethane was obtained via the conventional process. Bevacizumab (1.5 mg) was then incorporated into the dispersion and was subsequently dried to form the polymeric films. Films with dimensions of 3×3×1 mm that either did (group BPUI, n=10) or did not contain bevacizumab (group PUI, n=10) were implanted in the subconjunctival space, at the surgical site in 1 eye of each rabbit. The in vitro bevacizumab release was evaluated using size-exclusion high-performance liquid chromatography (HPLC), and the in vivo effects of the drug were investigated in a rabbit experimental trabeculectomy model by examining the bleb characteristics and collagen accumulation, and by performing immunohistological analyses of VEGF expression. HPLC showed that only 10% of the bevacizumab in the implants had been released by postoperative day 5. In vivo studies demonstrated that the drug had no adverse effects; however, no significant differences in either the bleb area score or the collagen deposit intensity between the group PUI and the group that BPUI were observed. Moreover, the group BPUI presented a significantly lower proportion of VEGF-expressing fibroblasts than group PUI (0.17±0.03 vs. 0.35±0.05 cells/field, P=0.005). This study demonstrated that bevacizumab release from the BPUIs only occurred for a short time probably from the surface of the films. Nevertheless, they were well tolerated in rabbit eyes and reduced the number of VEGF-expressing fibroblasts.